Literature DB >> 11241274

Frequent recognition of BCRF1, a late lytic cycle protein of Epstein-Barr virus, in the HLA-B*2705 context: evidence for a TAP-independent processing.

X Saulquin1, M Bodinier, M A Peyrat, A Hislop, E Scotet, F Lang, M Bonneville, E Houssaint.   

Abstract

Using a transient COS transfection assay, allowing a rapid estimation of the dominant CD8(+) T cell responses against a large number of HLA/viral protein combinations within polyclonal cell lines, we searched for HLA-B*2705-restricted CD8 T cell responses to Epstein-Barr virus (EBV) within T cell samples enriched for EBV-reactive cells. Among the 18 EBV proteins tested, only 2, the latent protein EBNA3A and the late lytic protein BCRF1 (viral IL-10), appeared dominant in the B27 context, as they triggered significant TNF and cytolytic responses in some donors. We provide evidence that the B27/BCRF1 epitope (RRLVVTLQC) is located in the signal sequence and that it can be presented in a TAP-independent manner. Using B27/BCRF1 monomeric complexes coated on immunomagnetic beads, we sorted out BCRF1-specific CD8 T cells from 8 of 15 HLA-B27(+) donors. This is, to our knowledge, the first demonstration of a recognition of BCRF1, suggesting that some immune control against EBV exists even during the late stage of the lytic cycle. This result also strengthens the unusual ability of HLA-B*2705 to present peptide in a TAP-independent manner.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11241274     DOI: 10.1002/1521-4141(200103)31:3<708::aid-immu708>3.0.co;2-5

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  6 in total

1.  CD8+ T cell responses to lytic EBV infection: late antigen specificities as subdominant components of the total response.

Authors:  Rachel J M Abbott; Laura L Quinn; Alison M Leese; Harry M Scholes; Annette Pachnio; Alan B Rickinson
Journal:  J Immunol       Date:  2013-10-21       Impact factor: 5.422

2.  Asymptomatic deficiency in the peptide transporter associated to antigen processing (TAP).

Authors:  H de la Salle; X Saulquin; I Mansour; S Klayme; D Fricker; J Zimmer; J-P Cazenave; D Hanau; M Bonneville; E Houssaint; G Lefranc; R Naman
Journal:  Clin Exp Immunol       Date:  2002-06       Impact factor: 4.330

3.  Innate immune modulation in EBV infection.

Authors:  Shunbin Ning
Journal:  Herpesviridae       Date:  2011-01-05

4.  CD8+ immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells.

Authors:  Victoria A Pudney; Alison M Leese; Alan B Rickinson; Andrew D Hislop
Journal:  J Exp Med       Date:  2005-01-31       Impact factor: 14.307

5.  +1 Frameshifting as a novel mechanism to generate a cryptic cytotoxic T lymphocyte epitope derived from human interleukin 10.

Authors:  Xavier Saulquin; Emmanuel Scotet; Lydie Trautmann; Marie-Alix Peyrat; Franck Halary; Marc Bonneville; Elisabeth Houssaint
Journal:  J Exp Med       Date:  2002-02-04       Impact factor: 14.307

6.  The vIL-10 gene of the Epstein-Barr virus (EBV) is conserved in a stable manner except for a few point mutations in various EBV isolates.

Authors:  Kyosuke Kanai; Yukio Satoh; Hiroyuki Yamanaka; Asako Kawaguchi; Kazutaka Horie; Kenji Sugata; Yoshiko Hoshikawa; Tetsutaro Sata; Takeshi Sairenji
Journal:  Virus Genes       Date:  2007-08-31       Impact factor: 2.198

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.